CleanRNA™ mRNA Synthesis
Integrated Production Process ensures the Quality of mRNA
- Low dsRNA
- Compresive Quality Control
- ISO13485 Certified Facility
Technology Platform
Arcegen has established three platform: Highly Specific Antibody Platform, Recombintant Protein Platform and mRNA Vaccine and drug Platform aimed to providing reagent and technique services for life scienc and biopharma industry.
Virus-like particles (VLPs)
High immunogenicity transmembrane proteins for antibody and vaccine development.
Discover your Antibody on Chip
Monoclonal Antibody Platform: Pioneering the Future of Antibody Discovery
- Shortening the antibody discovery time from 4-6 months to 1.5 months.
- Screening more than 14,000 cells simultaneously, ensuring the generation of monoclonal cell lines with a success rate exceeding 99% in just one week.